GLP1R and Stroke: However, trials of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in secondary prevention of major adverse cardiovascular events (MACE), including cardiovascular death, heart failure, stroke, and myocardial infarction (Vijan 2019).